ERBB2 and neoplasm: Most patients had tumor size >2 cm (56.0%), stage I/II (64.8%), lymph node invasion (48.8%), positive hormone receptor status such as ER+ (67.1%), PR+ (60.6%), or HER2+ (48.5%) and positive Ki67 (64.8%).